{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:53:16Z","timestamp":1792857196517,"version":"4.5.0"},"reference-count":45,"publisher":"Society of Nuclear Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2024,5,7]]},"published-print":{"date-parts":[[2024,8]]},"DOI":"10.2967\/jnumed.124.267469","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T16:40:32Z","timestamp":1718296832000},"page":"1250-1256","source":"Crossref","is-referenced-by-count":9,"title":["Synthesis of<sup>64<\/sup>Cu-,<sup>55<\/sup>Co-, and<sup>68<\/sup>Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In\u00a0Vivo Distribution Using Multiamine Macrocycles"],"prefix":"10.2967","volume":"65","author":[{"given":"German O.","family":"Fonseca Cabrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd E.","family":"Barnhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Aluicio-Sarduy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaifu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuedan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadalipura P.","family":"Rakesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zibo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Engle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"2024080105203300000_65.8.1250.1","unstructured":"Annual report to the nation 2022: overall cancer statistics. NIH website. https:\/\/seer.cancer.gov\/report_to_nation\/statistics.html. Updated December 20, 2023. Accessed May 15, 2024."},{"key":"2024080105203300000_65.8.1250.2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat Rev Dis Primers."},{"key":"2024080105203300000_65.8.1250.3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3390\/cancers15020461","article-title":"Metastatic prostate cancer: a review of current treatment options and promising new approaches","volume":"15","author":"Posdzich","year":"2023","journal-title":"Cancers (Basel)."},{"key":"2024080105203300000_65.8.1250.4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3390\/cancers11020268","article-title":"Targeted radionuclide therapy: new advances for improvement of patient management and response","volume":"11","author":"Malcolm","year":"2019","journal-title":"Cancers (Basel)."},{"key":"2024080105203300000_65.8.1250.5","first-page":"13N","article-title":"FDA approves Pluvicto\/Locametz for metastatic castration-resistant prostate cancer","volume":"63(5)","year":"2022","journal-title":"J Nucl Med."},{"key":"2024080105203300000_65.8.1250.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263274"},{"key":"2024080105203300000_65.8.1250.7","doi-asserted-by":"crossref","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist Updat."},{"key":"2024080105203300000_65.8.1250.8","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1093\/oncolo\/oyac216","article-title":"177Lu-PSMA therapy for metastatic castration-resistant prostate cancer: a mini-review of state-of-the-art","volume":"27","author":"AlSadi","year":"2022","journal-title":"Oncologist."},{"key":"2024080105203300000_65.8.1250.9","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/cancers13040779","article-title":"Preclinical and clinical status of PSMA-targeted alpha therapy for metastatic castration-resistant prostate cancer","volume":"13","author":"Juzeniene","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2024080105203300000_65.8.1250.10","doi-asserted-by":"crossref","first-page":"17588359231187202","DOI":"10.1177\/17588359231187202","article-title":"Novel radionuclide therapy combinations in prostate cancer","volume":"15","author":"Inderjeeth","year":"2023","journal-title":"Ther Adv Med Oncol."},{"key":"2024080105203300000_65.8.1250.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.243295"},{"key":"2024080105203300000_65.8.1250.12","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.3390\/cancers13163967","article-title":"PSMA-targeting radiopharmaceuticals for prostate cancer therapy: recent developments and future perspectives","volume":"13","author":"El Fakiri","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2024080105203300000_65.8.1250.13","first-page":"127","article-title":"Cytochemical markers and DNA content of neuroendocrine cells in carcinoma of the prostate gland during tumour progression","volume":"38","author":"Falkmer","year":"1990","journal-title":"Acta Histochem Suppl."},{"key":"2024080105203300000_65.8.1250.14","first-page":"128","article-title":"Function and molecular mechanisms of neuroendocrine cells in prostate cancer","volume":"29","author":"Huang","year":"2007","journal-title":"Anal Quant Cytol Histol."},{"key":"2024080105203300000_65.8.1250.15","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0022-5347(17)37390-1","article-title":"Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients","volume":"147","author":"Oesterling","year":"1992","journal-title":"J Urol."},{"key":"2024080105203300000_65.8.1250.16","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.21.24.8385-8397.2001"},{"key":"2024080105203300000_65.8.1250.17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1252"},{"key":"2024080105203300000_65.8.1250.18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209814"},{"key":"2024080105203300000_65.8.1250.19","first-page":"53","article-title":"Relevant genomics of neurotensin receptor in cancer","volume":"20","author":"Elek","year":"2000","journal-title":"Anticancer Res."},{"key":"2024080105203300000_65.8.1250.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0344-0338(87)80065-1"},{"key":"2024080105203300000_65.8.1250.21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.11.4673"},{"key":"2024080105203300000_65.8.1250.22","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(19970515)31:3<183::AID-PROS7>3.0.CO;2-M"},{"key":"2024080105203300000_65.8.1250.23","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.220157"},{"key":"2024080105203300000_65.8.1250.24","doi-asserted-by":"crossref","first-page":"20230042","DOI":"10.1002\/VIW.20230042","article-title":"Advances in macrocyclic chelators for positron emission tomography imaging","volume":"4","author":"Li","year":"2023","journal-title":"VIEW."},{"key":"2024080105203300000_65.8.1250.25","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.3390\/diagnostics11071235","article-title":"Production, purification, and applications of a potential theranostic pair: cobalt-55 and cobalt-58m","volume":"11","author":"Barrett","year":"2021","journal-title":"Diagnostics (Basel)."},{"key":"2024080105203300000_65.8.1250.26","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.3390\/molecules19044246","article-title":"Development of multi-functional chelators based on sarcophagine cages","volume":"19","author":"Liu","year":"2014","journal-title":"Molecules."},{"key":"2024080105203300000_65.8.1250.27","doi-asserted-by":"crossref","first-page":"1536012117711369","DOI":"10.1177\/1536012117711369","article-title":"Imaging neurotensin receptor in prostate cancer with 64Cu-labeled neurotensin analogs","volume":"16","author":"Deng","year":"2017","journal-title":"Mol Imaging."},{"key":"2024080105203300000_65.8.1250.28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/13543776.2021.1866539","article-title":"Therapeutic approaches targeting the neurotensin receptors","volume":"31","author":"Iyer","year":"2021","journal-title":"Expert Opin Ther Pat."},{"key":"2024080105203300000_65.8.1250.29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/jlcr.3581","article-title":"Radiopharmaceuticals for imaging and endoradiotherapy of neurotensin receptor-positive tumors","volume":"61","author":"Maschauer","year":"2018","journal-title":"J Labelled Comp Radiopharm."},{"key":"2024080105203300000_65.8.1250.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.185140"},{"key":"2024080105203300000_65.8.1250.31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.193847"},{"key":"2024080105203300000_65.8.1250.32","unstructured":". Fusion Pharmaceuticals announces first patient dosed in phase 1 study of FPI-2059, a targeted alpha therapy (TAT) for the treatment of solid tumors expressing NTSR1. Fusion Pharmaceuticals website. https:\/\/ir.fusionpharma.com\/2023-03-20-Fusion-Pharmaceuticals-Announces-First-Patient-Dosed-in-Phase-1-Study-of-FPI-2059,-a-Targeted-Alpha-Therapy-TAT-for-the-Treatment-of-Solid-Tumors-Expressing-NTSR1. Updated March 20, 2023. Accessed May 15, 2024."},{"key":"2024080105203300000_65.8.1250.33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2174\/1874471011666180418141357","article-title":"The production of Ac-225","volume":"11","author":"Engle","year":"2018","journal-title":"Curr Radiopharm."},{"key":"2024080105203300000_65.8.1250.34","doi-asserted-by":"crossref","unstructured":"Zhang T Ma X Xu M . Chelator boosted tumor-retention and pharmacokinetic properties: development of 64Cu labeled radiopharmaceuticals targeting neurotensin receptor. Eur J Nucl Med Mol Imaging. May 21, 2024 (Epub ahead of print].","DOI":"10.1007\/s00259-024-06754-2"},{"key":"2024080105203300000_65.8.1250.35","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.3390\/molecules27103062","article-title":"The chemical scaffold of theranostic radiopharmaceuticals: radionuclide, bifunctional chelator, and pharmacokinetics modifying linker","volume":"27","author":"Holik","year":"2022","journal-title":"Molecules."},{"key":"2024080105203300000_65.8.1250.36","doi-asserted-by":"crossref","first-page":"109883","DOI":"10.1016\/j.msec.2019.109883","article-title":"Surface potential and charges impact on cell responses on biomaterials interfaces for medical applications","volume":"104","author":"Metwally","year":"2019","journal-title":"Mater Sci Eng C Mater Biol Appl."},{"key":"2024080105203300000_65.8.1250.37","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1021\/acs.bioconjchem.2c00427","article-title":"Modular PET agent construction strategy through strain-promoted double-click reagent with efficient photoclick step","volume":"33","author":"Li","year":"2022","journal-title":"Bioconjugate Chem."},{"key":"2024080105203300000_65.8.1250.38","doi-asserted-by":"crossref","first-page":"108329","DOI":"10.1016\/j.nucmedbio.2023.108329","article-title":"Theranostic cobalt-55\/58m for neurotensin receptor-mediated radiotherapy in\u00a0vivo: a pilot study with dosimetry","volume":"118","author":"Lin","year":"2023","journal-title":"Nucl Med Biol."},{"key":"2024080105203300000_65.8.1250.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2007.05.012"},{"key":"2024080105203300000_65.8.1250.40","doi-asserted-by":"crossref","first-page":"110980","DOI":"10.1016\/j.apradiso.2023.110980","article-title":"Separation of cyclotron-produced cobalt-55\/58m from iron targets using cation exchange chromatography with non-aqueous solvents and extraction chromatography","volume":"200","author":"Lin","year":"2023","journal-title":"Appl Radiat Isot."},{"key":"2024080105203300000_65.8.1250.41","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1055\/s-0033-1338497","article-title":"Efficient synthesis of heterocyclic neurotensin receptor ligands by microwave-assisted aminocarbonylation","volume":"45","author":"Lang","year":"2013","journal-title":"Synthesis."},{"key":"2024080105203300000_65.8.1250.42","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1021\/acs.bioconjchem.4c00043","article-title":"Radiolabeling diaminosarcophagine with cyclotron-produced cobalt-55 and [55Co]Co-NT-Sarcage as a proof of concept in a murine xenograft model","volume":"35","author":"Lin","year":"2024","journal-title":"Bioconjugate Chem"},{"key":"2024080105203300000_65.8.1250.43","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1021\/acs.bioconjchem.2c00214","article-title":"Examination of charge modifications of an endolysosomal trapping inhibitor in an antagonistic NTSR1-targeted construct for colon cancer","volume":"33","author":"Fan","year":"2022","journal-title":"Bioconjug Chem."},{"key":"2024080105203300000_65.8.1250.44","doi-asserted-by":"crossref","first-page":"114241","DOI":"10.1016\/j.ejmech.2022.114241","article-title":"Examination of the impact molecular charge has on NTSR1-targeted agents incorporated with cysteine protease inhibitors","volume":"234","author":"Fan","year":"2022","journal-title":"Eur J Med Chem."},{"key":"2024080105203300000_65.8.1250.45","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejmech.2019.05.068","article-title":"Enhanced tumor retention of NTSR1-targeted agents by employing a hydrophilic cysteine cathepsin inhibitor","volume":"177","author":"Fan","year":"2019","journal-title":"Eur J Med Chem."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.267469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T12:25:33Z","timestamp":1722515133000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.267469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.2967\/jnumed.124.267469"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.267469","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]}}}